Drugs / Comirnaty Omicron XBB1.5
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05075538 | Dec 2021 → Jan 2024 | cancer | Jules Bordet Institute | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06181292 Comparator | Nov 2023 → Jun 2024 | COVID-19 | Hipra Scientific, S.L.U | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Comirnaty Omicron XBB1.5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06181292 ↗ |
| Modality | Vaccine | “Comirnaty vaccine arm” NCT06181292 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06181292 ↗ |